SIREN : 514656594
NEW MEDICAL CONCEPT - NMC is a French company founded 16 years ago, specialized in the sector Activités des sociétés holding. Based in MEYREUIL (13590), this company of category ETI shows in 2025 a revenue of 23.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2022 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23 802 687 € | 23 307 942 € | 21 783 360 € | 23 888 907 € | 14 245 386 € | 12 207 409 € | 10 978 397 € | 10 765 774 € | 9 176 439 € |
| Net income | 2 115 107 € | 2 275 632 € | 3 084 375 € | 806 783 € | 524 278 € | 396 913 € | -884 753 € | 608 908 € | 386 678 € |
| EBITDA | 1 079 718 € | 984 012 € | 1 250 009 € | 921 442 € | 656 350 € | 354 475 € | 253 893 € | 899 452 € | 441 715 € |
| Net margin | 8.9% | 9.8% | 14.2% | 3.4% | 3.7% | 3.3% | -8.1% | 5.7% | 4.2% |
In 2025, NEW MEDICAL CONCEPT - NMC achieves revenue of 23.8 M€. Over the period 2016-2025, the company shows strong growth with a CAGR (compound annual growth rate) of +11.2%. Vs 2024: +2%. After deducting consumption (13.1 M€), gross margin stands at 10.7 M€, i.e. a rate of 45%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 1.1 M€, representing 4.5% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 2.1 M€, i.e. 8.9% of revenue. This profit can be retained or distributed to shareholders.
23 802 687 €
10 725 421 €
1 079 718 €
961 722 €
2 115 107 €
4.5%
The debt ratio (= Financial debt / Equity x 100) stands at 655%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 12%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 20.8 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 9.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
654.796%
11.786%
9.928%
20.785
24.5%
In 2025, the debt ratio of NEW MEDICAL CONCEPT - NMC (654.80) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2025, the financial autonomy of NEW MEDICAL CONCEPT - NMC (11.8%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2025, the repayment capacity of NEW MEDICAL CONCEPT - NMC (20.79) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 883.85. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 20.7x. Operating income very largely covers interest expenses: high safety margin.
883.85
20.739
In 2025, the liquidity ratio of NEW MEDICAL CONCEPT - NMC (883.85) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2025, the interest coverage of NEW MEDICAL CONCEPT - NMC (20.7x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 583 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 88 days. The gap of 495 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 915 days of revenue, i.e. 60.5 M€ to permanently finance. Over 2016-2025, WCR increased by +968%, requiring additional financing.
60 471 916 €
583 j
88 j
0 j
915 j
Indicative estimate only : the number of comparable transactions in this sector is limited (20 transactions). This range of 7 331 447€ to 28 280 843€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 20 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare NEW MEDICAL CONCEPT - NMC with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of NEW MEDICAL CONCEPT - NMC in 2025 is 23.8 M€.
Yes, NEW MEDICAL CONCEPT - NMC generated a net profit of 2.1 M€ in 2025.
The headquarters of NEW MEDICAL CONCEPT - NMC is located in MEYREUIL (13590), in the department Bouches-du-Rhone.
The tax return of NEW MEDICAL CONCEPT - NMC is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
NEW MEDICAL CONCEPT - NMC operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.